Your browser doesn't support javascript.
loading
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.
Saini, Neeraj Y; Swoboda, David M; Greenbaum, Uri; Ma, Junsheng; Patel, Romil D; Devashish, Kartik; Das, Kaberi; Tanner, Mark R; Strati, Paolo; Nair, Ranjit; Fayad, Luis; Ahmed, Sairah; Lee, Hun Ju; Iyer, Swaminathan P; Steiner, Raphael; Jain, Nitin; Nastoupil, Loretta; Loghavi, Sanam; Tang, Guilin; Bassett, Roland L; Jain, Preetesh; Wang, Michael; Westin, Jason R; Green, Michael R; Sallman, David A; Padron, Eric; Davila, Marco L; Locke, Frederick L; Champlin, Richard E; Garcia-Manero, Guillermo; Shpall, Elizabeth J; Kebriaei, Partow; Flowers, Christopher R; Jain, Michael D; Wang, Feng; Futreal, Andrew P; Gillis, Nancy; Neelapu, Sattva S; Takahashi, Koichi.
Affiliation
  • Saini NY; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Swoboda DM; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Greenbaum U; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida.
  • Ma J; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Patel RD; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Devashish K; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Das K; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tanner MR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Strati P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Nair R; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fayad L; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ahmed S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lee HJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Iyer SP; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Steiner R; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jain N; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Nastoupil L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Loghavi S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tang G; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bassett RL; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jain P; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Westin JR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Green MR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sallman DA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Padron E; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida.
  • Davila ML; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida.
  • Locke FL; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.
  • Champlin RE; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.
  • Garcia-Manero G; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shpall EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Flowers CR; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jain MD; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang F; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.
  • Futreal AP; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gillis N; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Neelapu SS; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida.
  • Takahashi K; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.
Blood Cancer Discov ; 3(5): 385-393, 2022 09 06.
Article in En | MEDLINE | ID: mdl-35533245
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Large B-Cell, Diffuse / Neurotoxicity Syndromes Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Blood Cancer Discov Year: 2022 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Large B-Cell, Diffuse / Neurotoxicity Syndromes Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Blood Cancer Discov Year: 2022 Document type: Article Country of publication: